TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27940512

Group type: EXPERIMENTAL
Intervention: Announcement training
Number of subjects: 17173

Group type: COMPARATOR
Intervention: Conversation training
Number of subjects: 17173

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 17173
Study: 25599932

Group type: EXPERIMENTAL
Intervention: ROC AUC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Net benefit methods
Number of subjects: 0
Study: 23998375

Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS (1.5 mg/ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 24
Study: 21390978

Group type: EXPERIMENTAL
Intervention: Audio pillow with hypnosis text and relaxation music (n = 44)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 20082245

Group type: EXPERIMENTAL
Intervention: Combined Chinese drugs (Shengmai Injection by intravenous dripping and Gujin Granule by oral intake) plus Navelbine and Cisplatin (NP) chemotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Navelbine and Cisplatin (NP) chemotherapy alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combined Chinese drugs (Shengmai Injection and Gujin Granule) plus NP chemotherapy
Number of subjects: 63
Study: 17908569

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham acupuncture (invasive sham)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison between Acupuncture and Sham acupuncture
Number of subjects: 17
Study: 15541450

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 107

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Tetracosactide
Number of subjects: 107
Study: 11985183

Group type: EXPERIMENTAL
Intervention: Increased certainty (90% chance of developing AD)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Decreased certainty (50% chance of developing AD)
Number of subjects: 449
Study: 9385493

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d (30 patients with 37 lesions)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Aspirin 81 mg/d (40 patients with 45 lesions)
Number of subjects: 70
Study: 7944044

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass procedures with GI complications
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass procedures with longer pump and cross-clamp times
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Redo procedures
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Use of an intra-aortic balloon pump
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: GI complications
Number of subjects: 64
Study: 2688781

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of pimozide and lithium
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 57914

Group type: EXPERIMENTAL
Intervention: High doses of gamma globulin
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Low doses of gamma globulin
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 148
Study: 30790529

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Mefenamic acid capsules
Number of subjects: 43
Study: 24794767

Group type: EXPERIMENTAL
Intervention: Complete compromise (Group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Incomplete compromise (Group B)
Number of subjects: 44
Study: 22612302

Group type: COMPARATOR
Intervention: Double plateletpheresis (DP)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Triple plateletpheresis (TP)
Number of subjects: 411
Study: 21599896

Group type: EXPERIMENTAL
Intervention: Breathlessness Intervention Service (BIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 19144148

Group type: EXPERIMENTAL
Intervention: Progressive resistance training at 80% of peak strength, progressing 3% per session, 3 days per week for 6 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-exercise group (completed all exercises except hip adduction, without added resistance or progression).
Number of subjects: 0
Study: 22879633

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (diet and physical activity)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice a day
Number of subjects: 680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Estrogen users
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Non-estrogen users
Number of subjects: 680
Study: 16018774

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No epidural analgesia (group II)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (group III, non-pre-eclamptic)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No epidural analgesia (group IV, normotensive)
Number of subjects: 100
Study: 12358384

Group type: EXPERIMENTAL
Intervention: Training sessions in the Neer system
Number of subjects: 14

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Training sessions for specialists
Number of subjects: 14
Study: 9709932

Group type: EXPERIMENTAL
Intervention: D‐AG (500 mg daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DL‐AG (1000 mg daily)
Number of subjects: 12
Study: 7659431

Group type: EXPERIMENTAL
Intervention: (S)‐ketamine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: (R)‐ketamine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ketamine (unspecified form)
Number of subjects: 23
Study: 2228629

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) for active tuberculosis patients
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) for preventive therapy patients
Number of subjects: 205
Study: 369921

Group type: EXPERIMENTAL
Intervention: Ciclazindol (50 mg b.d.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Amitriptyline (50 mg b.d.)
Number of subjects: 35
Study: 11249050

Group type: EXPERIMENTAL
Intervention: Chemotherapy with cisplatin 100 mg/m2 on day 1 and vinorelbine 30 mg/m2 on days 1, 8, 15, 22, with cycles repeated every four weeks (arm A)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Chemotherapy with cisplatin and vinorelbine plus early WBRT 30 Gy/10 fx/12 days (arm B)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Delayed WBRT (arm A)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Early WBRT (arm B)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 176
Study: 30073688

Group type: EXPERIMENTAL
Intervention: Planned vaginal delivery
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Planned cesarean delivery
Number of subjects: 1435
Study: 29421247

Group type: EXPERIMENTAL
Intervention: Routine pain screening
Number of subjects: 60
Study: 27788820

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography (DE)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Right heart catheterization (RHC)
Number of subjects: 103
Study: 24760002

Group type: EXPERIMENTAL
Intervention: 7-valent conjugate vaccine (PCV7) followed by 23-valent polysaccharide vaccine (23vPPV) 6 months later
Number of subjects: 312

Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (23vPPV) alone
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 312
Study: 22528535

Group type: EXPERIMENTAL
Intervention: hCG treatment on day 0, 1, and 2 (Group III)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: hCG treatment on days 0 and 1 (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: hCG treatment on day 0 (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: hCG treatment (all groups)
Number of subjects: 40
Study: 21400792

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multi-component general anaesthesia (fentanyl, midazolam, propofol, rocuronium, artificial lung ventilation)
Number of subjects: 100
Study: 17885008

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein isolate (SPI+) (107 mg isoflavones/d)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Alcohol-washed soy protein isolate (SPI-) (<6 mg isoflavones/d)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 58
Study: 16329054

Group type: EXPERIMENTAL
Intervention: Dicloabak (diclofenac sodium 0.1% eyedrops without preservative)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Preserved diclofenac (diclofenac sodium 0.1% eyedrops with sodium merthiolate)
Number of subjects: 194
Study: 11973191

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 30
Study: 9465848

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg once daily, increased to 10 mg if necessary)
Number of subjects: 19193
Study: 7615109

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA)
Number of subjects: 100
Study: 2118272

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy for 4 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 365123

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All three drugs (Methylphenidate, Dextroamphetamine, Caffeine)
Number of subjects: 29
Study: 31645004

Group type: EXPERIMENTAL
Intervention: Simulation-based training on epilepsy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard child mannequin training on epilepsy
Number of subjects: 72
Study: 28663228

Group type: EXPERIMENTAL
Intervention: NADT with leuprolide acetate plus abiraterone acetate and prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leuprolide acetate alone
Number of subjects: 0
Study: 25937024

Group type: EXPERIMENTAL
Intervention: 12-week non-surgical treatment program (individualized progressed neuromuscular exercise, patient education, insoles, dietary advice, prescription of pain medication if indicated)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (two leaflets with information and advice on knee OA and recommended treatments)
Number of subjects: 100
Study: 23570296

Group type: EXPERIMENTAL
Intervention: Ceramic full-coverage CAD-CAM crown (Group 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ceramic full-coverage CAD-CAM crown (Group 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Composite full-coverage CAD-CAM crown (LPCpr, Group 3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Composite full-coverage CAD-CAM crown (SPCpr, Group 4)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ceramic CEREC machined endocrown (EndoCer, Group 5)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Composite CEREC machined endocrown (EndoCpr, Group 6)
Number of subjects: 48

Group type: COMPARATOR
Intervention: All groups (LPCpr, SPCpr, EndoCpr)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Different post lengths
Number of subjects: 48
Study: 22087850

Group type: EXPERIMENTAL
Intervention: Intensive implementation program for pharmacy project assistants
Number of subjects: 862

Group type: COMPARATOR
Intervention: Control group (written manual on EAFD and EASD implementation)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Intensive implementation program
Number of subjects: 862

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 862
Study: 18946878

Group type: EXPERIMENTAL
Intervention: P filter
Number of subjects: 67

Group type: COMPARATOR
Intervention: POV filter
Number of subjects: 67

Group type: COMPARATOR
Intervention: POVF filter
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All filters
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: POV and POVF filters
Number of subjects: 67
Study: 17135805

Group type: EXPERIMENTAL
Intervention: Home-based assessments using experimental instruments
Number of subjects: 644

Group type: COMPARATOR
Intervention: Clinic-based assessments during clinic visits
Number of subjects: 644
Study: 14592563

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study: 10224982

Group type: EXPERIMENTAL
Intervention: Prepartum and postpartum relapse prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prepartum relapse prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-help booklet only
Number of subjects: 0
Study: 8732377

Group type: COMPARATOR
Intervention: Streptokinase with subcutaneous heparin
Number of subjects: 553

Group type: COMPARATOR
Intervention: Streptokinase with intravenous heparin
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator with intravenous heparin
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Streptokinase plus tissue plasminogen activator with intravenous heparin
Number of subjects: 553
Study: 2008949

Group type: EXPERIMENTAL
Intervention: 1 mg midazolam
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2 mg midazolam
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3 mg midazolam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midazolam (1, 2, or 3 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midazolam (3 mg)
Number of subjects: 100
Study: 7043494

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 intravenously
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 22
Study: 31871250

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy without drain
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy with drain
Number of subjects: 50
Study: 31118157

Group type: EXPERIMENTAL
Intervention: Baseline blood IL-6
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Baseline leptin
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Baseline CRP
Number of subjects: 726
Study: 29100702

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 2008

Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stents (EES)
Number of subjects: 2008

Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 2008

Group type: COMPARATOR
Intervention: EES
Number of subjects: 2008
Study: 26383577

Group type: EXPERIMENTAL
Intervention: Dental health instruction before treatment
Number of subjects: 154

Group type: COMPARATOR
Intervention: Regular treatment (Control)
Number of subjects: 154
Study: 23281216

Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord blood (UCB) potentiated with recombinant human erythropoietin (rhEPO)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rhEPO) and placebo UCB
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo UCB and placebo rhEPO
Number of subjects: 96
Study: 20851046

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 18648258

Group type: EXPERIMENTAL
Intervention: 3D‐FLASH sequence
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 3D‐VIBE sequence
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison of image quality between 3D‐FLASH and 3D‐VIBE
Number of subjects: 34
Study: 17137977

Group type: EXPERIMENTAL
Intervention: Tecnis ZM001 IOL (AMO) (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR SA60D3 IOL (Alcon) (Group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SA40N IOL (AMO) (Group 1)
Number of subjects: 60
Study: 12518130

Group type: EXPERIMENTAL
Intervention: Magnifying colonoscopy
Number of subjects: 660

Group type: COMPARATOR
Intervention: Nonmagnifying colonoscopy
Number of subjects: 660
Study: 10685653

Group type: EXPERIMENTAL
Intervention: Concurrent biochemotherapy with cisplatin, vinblastine, and dacarbazine (CVD) plus IL-2 and IFN-alpha
Number of subjects: 1000

Group type: COMPARATOR
Intervention: CVD alone
Number of subjects: 1000
Study: 9590590

Group type: EXPERIMENTAL
Intervention: Rimexolone 1%
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 7512679

Group type: EXPERIMENTAL
Intervention: Ringer solution without antihistamines
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Haemaccel without antihistamines
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Antihistamines (dimetindene plus cimetidine)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 240
Study: 3343463

Group type: EXPERIMENTAL
Intervention: Sequential pulse defibrillation with four small mesh electrodes (6 cm2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sequential pulse defibrillation with two small (6 cm2) and two large (13 cm2) mesh electrodes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sequential pulse defibrillation with four large mesh electrodes (13 cm2)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Single pulse defibrillation with four small mesh electrodes (6 cm2)
Number of subjects: 21
Study: 31950265

Group type: EXPERIMENTAL
Intervention: Robot-group (image-free handheld robotic sculpting system)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (conventional alignment with intramedullary rods)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Robot-group
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 30074872

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 27088609

Group type: EXPERIMENTAL
Intervention: Hologram bracelet (n = 68)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo (n = 53)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control (n = 54)
Number of subjects: 175
Study: 25802309

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine administered to vaccine-naive children
Number of subjects: 50
Study: 23810742

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) meloxicam (0.2mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rectal insufflation of ozone (10 mL of 30 μg/mL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acupoint injection of ozone (0.5 mL of 30 μg/mL)
Number of subjects: 24
Study: 20656157

Group type: EXPERIMENTAL
Intervention: Wavefront-guided photorefractive keratectomy (PRK)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Wavefront-guided laser in situ keratomileusis (LASIK)
Number of subjects: 203
Study: 18385498

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream, applied twice weekly for 16 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo, applied twice weekly for 16 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream and Placebo
Number of subjects: 52
Study: 16369855

Group type: EXPERIMENTAL
Intervention: Pre-emptive antibiotic treatment with ceftriaxone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 20
Study: 12399736

Group type: EXPERIMENTAL
Intervention: Verteporfine (PDT)
Number of subjects: 609

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study: 10211086

Group type: EXPERIMENTAL
Intervention: CAF (400 mg/m2 cyclophosphamide, 25 mg/m2 doxorubicin, 500 mg/m2 5-fluorouracil)
Number of subjects: 415

Group type: COMPARATOR
Intervention: CMF (40 mg/m2 methotrexate, cyclophosphamide, 5-fluorouracil)
Number of subjects: 415
Study: 8775024

Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation for tension-type headaches
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation for migraine headaches
Number of subjects: 729

Group type: COMPARATOR
Intervention: No treatment, some types of mobilization and ice, amitriptyline (as control for tension-type headaches)
Number of subjects: 729
Study: 2169216

Group type: EXPERIMENTAL
Intervention: Standard heparin, 5000 units subcutaneously three times a day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin 3500 anti-Xa units subcutaneously once daily
Number of subjects: 41
Study: 670535

Group type: EXPERIMENTAL
Intervention: Structured Interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity Survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity Survey (scored by California scoring key)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with North America
Number of subjects: 0
Study: 6818583

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30561825

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard care with supportive positioning by parents
Number of subjects: 35
Study: 28370327

Group type: EXPERIMENTAL
Intervention: 0.2 mL of 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 0.6 mL of 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Heart rate changes
Number of subjects: 97
Study: 27678425

Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT) with lovastatin (40 mg/d), niacin (2.5 g/d), and colestipol (20 g/d) from 1989 to 2004, followed by double therapy with simvastatin (40–80 mg/d) and niacin from 2005 to 2006 and triple therapy of ezetimibe 10 mg and simvastatin 40 to 80 mg/d plus niacin during 2007 to 2012
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 175
Study: 24338597

Group type: EXPERIMENTAL
Intervention: Group-adapted physical exercises (10 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Instructional booklet (control)
Number of subjects: 60
Study: 22066583

Group type: EXPERIMENTAL
Intervention: Δ9-tetrahydrocannabinol (THC) inhalation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13